Results 161 to 170 of about 43,089 (386)
Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine
ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi +3 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1132-1140, April 2025.Abstract The main purpose of this project was to capture experts' opinion on hyperkalaemia management and form best practice recommendations for cardiorenal patients in Greece. A steering committee of nephrologists and cardiologists developed 37 statements. An online questionnaire completed by 32 experts in cardiorenal management in Greece.
Christina Chrysohoou +3 more
wiley +1 more source
Focus on HFpEF in heart failure
Chinese Medical Journal, 2022 Chunhui He +2 more
openaire +3 more sources
Clinical Phenogrouping and Systolic Performance in HFpEF
JACC: Heart Failure, 2020 Cohen et al. ([1][1]) identified the phenogroup of heart failure with preserved ejection fraction (HFpEF) that best responded to spironolactone in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) trial ([1][1]).
openaire +3 more sources
Myocardial transcription factors in diastolic dysfunction: clues for model systems and disease [PDF]
, 2016 [Abstract] There are multiple intrinsic mechanisms for diastolic dysfunction ranging from molecular to structural derangements in ventricular myocardium.
Mikhailov, Alexander T., Torrado, Mario
core +2 more sources
Heart Failure With Preserved Ejection Fraction and Adipose Tissue: A Story of Two Tales
Frontiers in Cardiovascular Medicine, 2019 Heart failure with preserved ejection fraction (HFpEF) is characterized by signs and symptoms of heart failure in the presence of a normal left ventricular ejection fraction.
Albin Oh +7 more
doaj +1 more source
ACE Inhibitor Prevents HFpEF Through Renin-angiotensin System Inhibition Independent Manner [PDF]
, 2014 Jun Tanno +8 more
openalex +1 more source
EDUCATIONAL CHALLENGES: HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) [PDF]
, 2015 openalex +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source